Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria-Victoria Mateos

Showing results (1-10 of 231) with videos related to

Pageof 24
Sort By:
The Lancet. Haematology|August 1, 2020
Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' replyMaria-Victoria Mateos, Saad Z Usmani
Blood Cancer Journal|March 22, 2019
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomidePhilippe Moreau, Elena Zamagni, Maria-Victoria Mateos
The Lancet. Haematology|February 3, 2022
Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practiceSagar Lonial, S Vincent Rajkumar, Maria Victoria Mateos
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Myeloma in Elderly Patients: When Less Is More and More Is MoreAshley Rosko, Sergio Giralt, Maria-Victoria Mateos, et al.
Blood Advances|June 3, 2026
Targeting BCMA in Patients with Relapsed/Refractory Multiple Myeloma in 1-3 Prior Lines of TherapyDoris K Hansen, Maria-Victoria Mateos, Luciano J Costa
Seminars in Hematology|April 25, 2009
Frontline treatment in elderly patients with multiple myelomaThierry Facon, Jesus San Miguel, Maria Victoria Mateos, et al.
British Journal of Haematology|April 4, 2022
How I treat triple-class refractory multiple myelomaLuciano J Costa, Vania Hungria, Mohamad Mohty, et al.
Blood Cancer Journal|September 5, 2022
Smoldering multiple myeloma current treatment algorithmsS Vincent Rajkumar, Shaji Kumar, Sagar Lonial, et al.
Expert Opinion on Investigational Drugs|May 25, 2012
Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDsEnrique M Ocio, Maria-Victoria Mateos, Jesus F San-Miguel
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2024
Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple MyelomaHang Quach, Gurdeep Parmar, Maria-Victoria Mateos, et al.
Pageof 24

Showing results (1-10 of 231) with videos related to

Sort By:
Pageof 24
The Lancet. Haematology|August 1, 2020
Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' replyMaria-Victoria Mateos, Saad Z Usmani
Blood Cancer Journal|March 22, 2019
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomidePhilippe Moreau, Elena Zamagni, Maria-Victoria Mateos
The Lancet. Haematology|February 3, 2022
Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practiceSagar Lonial, S Vincent Rajkumar, Maria Victoria Mateos
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Myeloma in Elderly Patients: When Less Is More and More Is MoreAshley Rosko, Sergio Giralt, Maria-Victoria Mateos, et al.
Blood Advances|June 3, 2026
Targeting BCMA in Patients with Relapsed/Refractory Multiple Myeloma in 1-3 Prior Lines of TherapyDoris K Hansen, Maria-Victoria Mateos, Luciano J Costa
Seminars in Hematology|April 25, 2009
Frontline treatment in elderly patients with multiple myelomaThierry Facon, Jesus San Miguel, Maria Victoria Mateos, et al.
British Journal of Haematology|April 4, 2022
How I treat triple-class refractory multiple myelomaLuciano J Costa, Vania Hungria, Mohamad Mohty, et al.
Blood Cancer Journal|September 5, 2022
Smoldering multiple myeloma current treatment algorithmsS Vincent Rajkumar, Shaji Kumar, Sagar Lonial, et al.
Expert Opinion on Investigational Drugs|May 25, 2012
Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDsEnrique M Ocio, Maria-Victoria Mateos, Jesus F San-Miguel
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2024
Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple MyelomaHang Quach, Gurdeep Parmar, Maria-Victoria Mateos, et al.
Pageof 24